These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29638149)

  • 1. Masitinib in treatment of pancreatic cancer.
    Waheed A; Purvey S; Saif MW
    Expert Opin Pharmacother; 2018 May; 19(7):759-764. PubMed ID: 29638149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of masitinib for treating systemic mastocytosis.
    Laforgia M; Marech I; Nardulli P; Calabrò C; Gadaleta CD; Ranieri G
    Expert Opin Pharmacother; 2019 Sep; 20(13):1539-1550. PubMed ID: 31381378
    [No Abstract]   [Full Text] [Related]  

  • 3. Masitinib for the treatment of mild to moderate Alzheimer's disease.
    Folch J; Petrov D; Ettcheto M; Pedrós I; Abad S; Beas-Zarate C; Lazarowski A; Marin M; Olloquequi J; Auladell C; Camins A
    Expert Rev Neurother; 2015 Jun; 15(6):587-96. PubMed ID: 25961655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
    Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
    Dubreuil P; Letard S; Ciufolini M; Gros L; Humbert M; Castéran N; Borge L; Hajem B; Lermet A; Sippl W; Voisset E; Arock M; Auclair C; Leventhal PS; Mansfield CD; Moussy A; Hermine O
    PLoS One; 2009 Sep; 4(9):e7258. PubMed ID: 19789626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
    Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.
    Prosvicova J; Lukesova S; Kopecky J; Grim J; Papik Z; Kolarova R; Navratilova B; Dubreuil P; Agopian J; Mansfield C; Moussy A; Hermine O
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):695-7. PubMed ID: 26725706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
    Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I
    Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
    Lee-Fowler TM; Guntur V; Dodam J; Cohn LA; DeClue AE; Reinero CR
    Int Arch Allergy Immunol; 2012; 158(4):369-74. PubMed ID: 22487554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis.
    Trias E; Ibarburu S; Barreto-Núñez R; Babdor J; Maciel TT; Guillo M; Gros L; Dubreuil P; Díaz-Amarilla P; Cassina P; Martínez-Palma L; Moura IC; Beckman JS; Hermine O; Barbeito L
    J Neuroinflammation; 2016 Jul; 13(1):177. PubMed ID: 27400786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
    Turek M; Gogal R; Saba C; Vandenplas ML; Hill J; Feldhausser B; Lawrence J
    Res Vet Sci; 2014 Apr; 96(2):304-7. PubMed ID: 24602916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masitinib for the treatment of Alzheimer's disease.
    Ettcheto M; Cano A; Sanchez-López E; Verdaguer E; Folch J; Auladell C; Camins A
    Neurodegener Dis Manag; 2021 Aug; 11(4):263-276. PubMed ID: 34412534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
    Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
    BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
    Hamad AA; Amer BE; Hawas Y; Mabrouk MA; Meshref M
    Neurol Sci; 2024 May; 45(5):1861-1873. PubMed ID: 38105307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
    Humbert M; de Blay F; Garcia G; Prud'homme A; Leroyer C; Magnan A; Tunon-de-Lara JM; Pison C; Aubier M; Charpin D; Vachier I; Purohit A; Gineste P; Bader T; Moussy A; Hermine O; Chanez P
    Allergy; 2009 Aug; 64(8):1194-201. PubMed ID: 19614621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging protein kinase inhibitors for treating pancreatic cancer.
    Furuse J; Nagashima F
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):77-86. PubMed ID: 28253828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma.
    Rudloff U
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):345-368. PubMed ID: 36250721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
    Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
    Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging cell-cycle inhibitors for pancreatic cancer therapy.
    Bayraktar S; Rocha Lima CM
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):571-82. PubMed ID: 23126234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.